Normal pregnancy outcome after early maternal exposure to gonadotropin releasing hormone agonist. A case report.
An infertile woman was treated with leuprolide acetate in preparation for in vitro fertilization and was found to be pregnant after exposure to the gonadotropin releasing hormone agonist (GNRHa) from days 21-38 after her last menstrual period. She delivered a healthy-appearing, male infant at term. We found reports of four other pregnancies with early maternal GNRHa exposure. While no malformations have been reported, patients are advised to use barrier contraception when GNRHa therapy is initiated.
Ghazi
D M
DM
Department of Obstetrics and Gynecology, Robert Wood Johnson University Hospital, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick 08903.
Kemmann
E
E
Hammond
J M
JM
D000328:Adult; D000075202:Contraindications; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods*; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects / Q000031:analogs & derivatives*; D006728:Hormones / Q000009:adverse effects*; D006801:Humans; D016729:Leuprolide; D008597:Menstrual Cycle; D011247:Pregnancy; D011256:Pregnancy Outcome
D006728:Hormones; D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide